Bergendahl will be responsible for operational business at Rentschler Biopharma from April 1.   Photo credits: Rentschler Biopharma 

 

 

 

As announced by the company today, Dr Veit Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation on 1 April 2026.

 

Bergendahl succeeds Christiane Bardroff, who is leaving the company at her own request during this quarter. The new COO thus completes the executive board of the globally active CDMO headquartered in Laupheim (Biberach district), which appointed its supervisory board member Prof. Uwe Bücheler as interim managing director just three weeks ago.

 

Bergendahl, who holds a doctorate in biology, brings more than 20 years of international industry experience in leadership roles in biopharmaceutical development and manufacturing. Most recently, he was Head of Clinical Supply Biologicals at Boehringer Ingelheim, where he was responsible for the commissioning and go-live of the Biologicals Development Centre at the research and development site in Biberach. Since 2023, he has been in charge of the single-use facility for clinical manufacturing with 2x2,000L bioreactors.
 

Source: Press release, Rentschler Biopharma, 12.02.2026